References

  1. Jager, R.D. et al, Age-related macular degeneration. N Engl J Med 2008. 358(24): 2606-17.
  2. Lechanteur Y. et al: Association of Smoking and CFH and ARMS2 Risk Variants With Younger Age at Onset of Neovascular Age-Related Macular Degeneration; JAMA Ophthalmol 2015;133(5):533-541
  3. Seddon J.M. et al. Prediction Model for Prevalence and Incidence of Advanced Age-Related Macular Degeneration Based on Genetic, Demographic and Environmental Variables.IOVS 2009;50(5):2044-2053.
  4. Yu, Y. et al: Prospective Assessment of Genetic Effects on Progression to Different Stages of Age-Related Macular Degeneration Using Multistate Markov Models; IOVS 2012; 53(3):1548-1556
  5. Awh, C.C. et al, Treatment response to antioxidants and zinc based on CFH and ARMS2 genetic risk allele number in the Age-Related Eye Disease Study. Ophthalmology, 2015; 122(1):162-9.
  6. Seddon, J.M. et al, Validation of a Prediction Algorithm for Progression to Advanced Macular Degeneration Subtypes. JAMA Ophthalmol. 2013;131(4):448-455
  7. Seddon, J.M. et al, The US twin study of age-related macular degeneration: relative roles of genetic and environmental influences. Arch Ophthalmol 2005; 23(3): 321-7.
  8. Age-Related Eye Disease Study Research Group, A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol 2001; 119(10): 1417-36.
  9. Awh, C.C. et al.,CFH and ARMS2 Genetic Polymorphisms Predict Response to Antioxidants and Zinc in Patients with Age-related Macular Degeneration. Ophthalmology, 2013 Nov;120(11):2317-23. doi: 10.1016/j.ophtha.2013.07.039. Epub 2013 Aug 21.
  10. Chew, E.Y. et al. Age-Related Eye Disease Study 2 (AREDS2) Research Group; Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA 2013;309(19) :2005-2015.
  11. Seddon J.M. et al; Prediction Model for Prevalence and Incidence of Advanced Age-Related Macular Degeneration Based on Genetic, Demographic and Environmental Variables. IOVS 2009;50(5):2044-2053
  12. Seddon J. M, Silver R. E, Rosner B. Response to AREDS supplements according to genetic factors: survival analysis approach using the eye as the unit of analysis. Br J Ophthalmol doi:10.1136/bjophthalmol-2016-308624
  13. Chew, E.Y. et al. No clinically significant association between CFH and ARMS2 genotypes and response to nutritional supplements: AREDS report number 38. Ophthalmology. 2014 Nov;121(11):2173-80.